OAG
TEVA icon

Orbis Allan Gray’s Teva Pharmaceuticals TEVA Stock Holding History

Orbis Allan Gray’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,942,091
Closed -$76.2M – 64
2018
Q4 		$76.2M Buy
4,942,091
+2,850,488
+136% +$58.4M 0.55% 32
2018
Q3 		$45.1M Buy
+2,091,603
New +$48.6M 0.26% 38

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Orbis Allan Gray's TEVA Position: Q1 2019 in Review

Orbis Allan Gray sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 4,942,091 shares — an estimated $76.2M sold.

Orbis Allan Gray first reported a position in TEVA in Q3 2018 and held it in 2 quarters. The position peaked at $76.2M in Q4 2018. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Orbis Allan Gray reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Orbis Allan Gray sold 4,942,091 Teva Pharmaceuticals shares in Q1 2019, an estimated $76.2M.
  • Orbis Allan Gray first reported a position in Teva Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Orbis Allan Gray's Teva Pharmaceuticals position peaked at $76.2M in Q4 2018.
  • 522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Orbis Allan Gray's 13F filing for Q1 2019, filed 15 May 2019.